1. Academic Validation
  2. DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression

DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression

  • Funct Integr Genomics. 2024 Jan 17;24(1):12. doi: 10.1007/s10142-024-01293-3.
Zanbin Li # 1 Yong Ying # 1 Xiangtai Zeng # 1 Jiafeng Liu 1 Yang Xie 1 Zefu Deng 1 Zhiqiang Hu 1 Junjie Yang 2
Affiliations

Affiliations

  • 1 Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical College, No. 128, Jinling West Road, Ganzhou, 341000, Jiangxi, People's Republic of China.
  • 2 Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical College, No. 128, Jinling West Road, Ganzhou, 341000, Jiangxi, People's Republic of China. Yangjj151@163.com.
  • # Contributed equally.
Abstract

Promoter methylation is one of the most studied epigenetic modifications and it is highly relevant to the onset and progression of thyroid carcinoma (THCA). This study investigates the promoter methylation and expression pattern of intercellular adhesion molecule 5 (ICAM5) in THCA. CpG islands with aberrant methylation pattern in THCA, and the expression profiles of the corresponding genes in THCA, were analyzed using bioinformatics. ICAM5 was suggested to have a hypermethylation status, and it was highly expressed in THCA tissues and cells. Its overexpression promoted proliferation, mobility, and tumorigenic activity of THCA cells. As for the downstream signaling, ICAM5 was found to activate the MAPK/ERK and MAPK/JNK signaling pathways. Either inhibition of ERK or JNK blocked the oncogenic effects of ICAM5. DNA methyltransferases 1 (DNMT1) and DNMT3a were found to induce promoter hypermethylation of ICAM5 in THCA cells. Knockdown of DNMT1 or DNMT3a decreased the ICAM5 expression and suppressed malignant properties of THCA cells in vitro and in vivo, which were, however, restored by further artificial ICAM5 overexpression. Collectively, this study reveals that DNMT1 and DNMT3a mediates promoter hypermethylation and transcription activation of ICAM5 in THCA, which promotes malignant progression of THCA through the MAPK signaling pathway.

Keywords

DNMT1/DNMT3a; ICAM5; MAPK signaling pathway; Promoter hypermethylation; Thyroid carcinoma.

Figures
Products